ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
122.350,38
0,92%
S&P 500
5.996,66
1,00%
US Dollar vs BRL
6,08068
0,00%
Bitcoin
104.256,08
0,13%
Brent Oil
80,005
0,00%
As Melhores Corretoras Online
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Harrow Inc (HROW)

  7. Harrow Inc (HROW) Notícias

HROW

Harrow (HROW)

Harrow Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:HROW
DataHoraFonteTítuloCódigoCompanhia
07/01/202509:00Business WireHarrow Appoints Amir H. Shojaei as Chief Scientific OfficerNASDAQ:HROWHarrow Inc
21/11/202409:00Business WireHarrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.NASDAQ:HROWHarrow Inc
20/11/202409:00Business WireMelt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract SurgeryNASDAQ:HROWHarrow Inc
15/11/202409:00Business WireHarrow Announces Participation in Upcoming Investor ConferencesNASDAQ:HROWHarrow Inc
13/11/202418:34Business WireHarrow Announces Third Quarter 2024 Financial ResultsNASDAQ:HROWHarrow Inc
13/11/202409:00Business WireHarrow Launches Access and Affordability Program with Price Reductions for Branded ProductsNASDAQ:HROWHarrow Inc
12/11/202409:00Business WireHarrow Announces Market Access Wins for VEVYE®NASDAQ:HROWHarrow Inc
07/11/202409:00Business WireHarrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow’s Branded Eyecare ProductsNASDAQ:HROWHarrow Inc
31/10/202408:00Business WireHarrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024NASDAQ:HROWHarrow Inc
10/10/202408:00Business WireMelt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract SurgeryNASDAQ:HROWHarrow Inc
03/10/202408:00Business WireHarrow Relaunches TRIESENCE®NASDAQ:HROWHarrow Inc
25/09/202413:02Business WireHarrow Announces Nashville ExpansionNASDAQ:HROWHarrow Inc
03/09/202408:00Business WireHarrow to Present at Three Investor Conferences in September in New YorkNASDAQ:HROWHarrow Inc
07/08/202418:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:HROWHarrow Inc
07/08/202417:33Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HROWHarrow Inc
07/08/202417:01Business WireHarrow Announces Second Quarter 2024 Financial ResultsNASDAQ:HROWHarrow Inc
25/07/202408:00Business WireHarrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024NASDAQ:HROWHarrow Inc
12/07/202408:00Business WireHarrow to Attend 2024 ASRS Annual MeetingNASDAQ:HROWHarrow Inc
09/07/202408:00Business WireHarrow Enters into 340B Prime Vendor Program Contract with Apexus™ for IHEEZO® and Other Key Harrow ProductsNASDAQ:HROWHarrow Inc
20/06/202408:00Business WireHarrow Provides TRIESENCE® Relaunch UpdateNASDAQ:HROWHarrow Inc
06/06/202409:00Business WireMelt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract SurgeryNASDAQ:HROWHarrow Inc
05/06/202408:00Business WireHarrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension StudyNASDAQ:HROWHarrow Inc
15/05/202408:00Business WireHarrow to Present at Two Investor Conferences in MayNASDAQ:HROWHarrow Inc
13/05/202417:01Business WireHarrow Announces First Quarter 2024 Financial ResultsNASDAQ:HROWHarrow Inc
13/05/202408:00Business WireHarrow Names Greg DiPasquale as Senior Vice President, Head of CommercialNASDAQ:HROWHarrow Inc
25/04/202408:00Business WireHarrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024NASDAQ:HROWHarrow Inc
02/04/202409:16Business WireMelt Pharmaceuticals Closes $24 Million Series B Preferred Stock FinancingNASDAQ:HROWHarrow Inc
20/03/202408:15IH Market NewsJPMorgan boosts dividends, Chipotle unveils 50:1 stock split, and Latest NewsNASDAQ:HROWHarrow Inc
19/03/202418:45Business WireHarrow Announces Fourth Quarter and Year-End 2023 Financial ResultsNASDAQ:HROWHarrow Inc
19/03/202408:27IH Market NewsUS Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices RetreatNASDAQ:HROWHarrow Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:HROW

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
COGN3
COGNA ON
BOV
BRAV3
Brava Energia ON
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
PMAM3
PARANAPANEMA ON
BOV
AMOB3
Automob Participacoes ON
BOV
FNAM11
Fundo Invest Amazonia Fi...
BOV
HBRE3
HBR Realty Empreendiment... ON
BOV
PRIO3
PETRORIO ON
BOV
AMER3
Americanas ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados